Transdermal oxybutynin moves towards Japanese filing for overactive bladder
This article was originally published in Scrip
Executive Summary
Hisamitsu is planning to file for the Japanese approval of a transdermal therapy for the treatment of overactive bladder symptoms following positive results from a Phase III trial with the adhesive patch product.